"Kr\u00E1tkodob\u00FD efekt l\u00E9\u010Dby srde\u010Dn\u00EDho selh\u00E1n\u00ED na v\u00FDvoj glomerul\u00E1rn\u00ED filtrace u star\u0161\u00EDch pacient\u016F s kardioren\u00E1ln\u00EDm syndromem"@cs . "Short-Term Effect of Evidence Based Medicine Heart Failure Therapy on Glomerular Fitration Rate in Elderly Patients with"@en . . "N" . "Background: impaired renal function is a strong predictor of mortality in chronic heart failure (CHF) patients. Chronic kidney disease (CKD) is common commorbidity in CHF patients of advanced age. Study objective: to assess the effect of Evidence Based Medicine CHF therapy in elderly patients with CHF and CKD. Patients population and methods: 52 elderly patients, 36 male and 16 female with CHF. Mean age 82 years (72-90), NYHA class II-IV, mean left ventricular ejection fraction (LVEF) 36%, mean creatinine level 215 mol/l and estimated glomerular filtration rate (eGFR) 0,53 ml/sec/1.73 m2. Patients were followed by cardiologist and nefrologist in a out-patient tertiary care clinic. Clinical and laboratory parameters from the first and the most recent clinic visit were evaluated. Patients were treated according to guidelines for the management of CHF. Results: At the most recent clinic visit, 96% were treated by betablockers, 70% by ACE inhibitor (ACEI), 22% by angiotensin receptor blockers (ARB), 78% by ACEIs and/or ARBs, 78% by aldosteron antagonists. After mean follow-up of 222 55 days, there was significant improvement in NYHA class (p=0,015), significant increase in LV EF (p<0,0001) and decrease in estimated pulmonary artery pressure (p<0,00001). Mean change of eGRF was not significant (from 0,53 to 0,48 ml/sec., p = 0,075). Conclusion: short term Evidence Based Medicine CHF therapy in elderly patients with CHF and CKD was associated with the improvement of the clinical and hemodynamical parameters, but not with the significant decrease of glomerular filtration rate."@en . . . "chronic heart failure, chronic kidney disease, pharmacotherapy, elderly"@en . "Kr\u00E1tkodob\u00FD efekt l\u00E9\u010Dby srde\u010Dn\u00EDho selh\u00E1n\u00ED na v\u00FDvoj glomerul\u00E1rn\u00ED filtrace u star\u0161\u00EDch pacient\u016F s kardioren\u00E1ln\u00EDm syndromem"@cs . . . "[20399FC819B2]" . . "\u00DAvod: Ren\u00E1ln\u00ED insuficience je nejsiln\u011Bj\u0161\u00EDm rizikov\u00FDm faktorem mortality pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm. Kombinovan\u00E1 srde\u010Dn\u00ED a ren\u00E1ln\u00ED insuficience je ozna\u010Dov\u00E1na jako kardioren\u00E1ln\u00ED syndrom. P\u00E9\u010De o nemocn\u00E9 s kardioren\u00E1ln\u00EDm syndromem vy\u017Eaduje spolupr\u00E1ci kardiologa a nefrologa. Krom\u011B terapie srde\u010Dn\u00EDho selh\u00E1n\u00ED je nutn\u00E9 se v\u011Bnovat specifick\u00FDm l\u00E9\u010Debn\u00FDm postup\u016Fm u ren\u00E1ln\u00ED insuficience: l\u00E9\u010Dba ren\u00E1ln\u00ED an\u00E9mie, korekce acid\u00F3zy, korekce poruch kalciofosf\u00E1tov\u00E9ho metabolizmu, l\u00E9\u010Dba hyperurik\u00E9mie. C\u00EDle pr\u00E1ce: zhodnotit vliv multidisciplin\u00E1rn\u00EDho p\u0159\u00EDstupu na v\u00FDvoj klinick\u00FDch a laboratorn\u00EDch parametr\u016F u pacient\u016F s kardioren\u00E1ln\u00EDm syndromem. Zhodnotit l\u00E9\u010Dbu nemocn\u00FDch. Soubor nemocn\u00FDch a metodika: ambulantn\u00ED pacienti spl\u0148uj\u00EDc\u00ED Framinghamsk\u00E1 kriteria srde\u010Dn\u00EDho selh\u00E1n\u00ED s ren\u00E1ln\u00ED insuficienc\u00ED s glomerul\u00E1rn\u00ED filtrac\u00ED (GFR) < 60 ml/min (< 1ml/sec). Retrospektivn\u00ED anal\u00FDza klinick\u00FDch a laboratorn\u00EDch ukazatel\u016F z prvn\u00ED a posledn\u00ED n\u00E1v\u0161t\u011Bvy ve specializovan\u00E9 ambulanci. V\u00FDsledky: V roce 2005 za\u0159azeni 23 pacienti, 16 mu\u017E\u016F a 7 \u017Een pr\u016Fm\u011Brn\u00FDm v\u011Bkem 72 let, NYHA II-IV, EF LK 36%, pr\u016Fm\u011Brnou koncentrac\u00ED kreatininu 215 mol/l a GFR 0,53 ml/sec. Hospitalizov\u00E1ni do 1 roku byli 4 pacienti a 2 pacienti zem\u0159eli. Pacienti byli l\u00E9\u010Deni: betablok\u00E1tory (96%), inhibitory ACE (70%), sartany (22%), ACEi nebo sartany (78%), spironolaktonem (78%), erytropoetinem (22%). U 19 pacient\u016F s pr\u016Fm\u011Brnou dobou sledov\u00E1n\u00ED 222 55 dn\u00ED do\u0161lo ke zlep\u0161en\u00ED t\u0159\u00EDdy NYHA (p=0,015), zv\u00FD\u0161en\u00ED ejek\u010Dn\u00ED frakce LK (p<0,0001) a poklesu tlaku v plicnici hodnocen\u00E9m neinvazivn\u011B (p<0,00001). Zm\u011Bna GRF nebyla v\u00FDznamn\u00E1 (z 0,53 na 0,48 ml/sec., p = 0,075). Z\u00E1v\u011Bry: multidisciplin\u00E1rn\u00ED p\u0159\u00EDstup v p\u00E9\u010Di o nemocn\u00E9 s kardioren\u00E1ln\u00EDm syndromem je spojen s klinick\u00FDm a hemodynamick\u00FDm zlep\u0161en\u00EDm, nedoch\u00E1z\u00ED ke zhor\u0161en\u00ED ren\u00E1ln\u00EDch funkc\u00ED v kr\u00E1tk\u00E9m \u010Dasov\u00E9m horizontu i p\u0159i pou\u017Eit\u00ED modern\u00ED agresivn\u00ED farmakoterapie srde\u010Dn\u00EDho selh\u00E1n\u00ED."@cs . "RIV/00023884:_____/09:#0003601!RIV12-MZ0-00023884" . "RIV/00023884:_____/09:#0003601" . "Kr\u00E1tkodob\u00FD efekt l\u00E9\u010Dby srde\u010Dn\u00EDho selh\u00E1n\u00ED na v\u00FDvoj glomerul\u00E1rn\u00ED filtrace u star\u0161\u00EDch pacient\u016F s kardioren\u00E1ln\u00EDm syndromem" . "2"^^ . "Journal of American Geriatric Society" . "4"^^ . . . "\u00DAvod: Ren\u00E1ln\u00ED insuficience je nejsiln\u011Bj\u0161\u00EDm rizikov\u00FDm faktorem mortality pacient\u016F se srde\u010Dn\u00EDm selh\u00E1n\u00EDm. Kombinovan\u00E1 srde\u010Dn\u00ED a ren\u00E1ln\u00ED insuficience je ozna\u010Dov\u00E1na jako kardioren\u00E1ln\u00ED syndrom. P\u00E9\u010De o nemocn\u00E9 s kardioren\u00E1ln\u00EDm syndromem vy\u017Eaduje spolupr\u00E1ci kardiologa a nefrologa. Krom\u011B terapie srde\u010Dn\u00EDho selh\u00E1n\u00ED je nutn\u00E9 se v\u011Bnovat specifick\u00FDm l\u00E9\u010Debn\u00FDm postup\u016Fm u ren\u00E1ln\u00ED insuficience: l\u00E9\u010Dba ren\u00E1ln\u00ED an\u00E9mie, korekce acid\u00F3zy, korekce poruch kalciofosf\u00E1tov\u00E9ho metabolizmu, l\u00E9\u010Dba hyperurik\u00E9mie. C\u00EDle pr\u00E1ce: zhodnotit vliv multidisciplin\u00E1rn\u00EDho p\u0159\u00EDstupu na v\u00FDvoj klinick\u00FDch a laboratorn\u00EDch parametr\u016F u pacient\u016F s kardioren\u00E1ln\u00EDm syndromem. Zhodnotit l\u00E9\u010Dbu nemocn\u00FDch. Soubor nemocn\u00FDch a metodika: ambulantn\u00ED pacienti spl\u0148uj\u00EDc\u00ED Framinghamsk\u00E1 kriteria srde\u010Dn\u00EDho selh\u00E1n\u00ED s ren\u00E1ln\u00ED insuficienc\u00ED s glomerul\u00E1rn\u00ED filtrac\u00ED (GFR) < 60 ml/min (< 1ml/sec). Retrospektivn\u00ED anal\u00FDza klinick\u00FDch a laboratorn\u00EDch ukazatel\u016F z prvn\u00ED a posledn\u00ED n\u00E1v\u0161t\u011Bvy ve specializovan\u00E9 ambulanci. V\u00FDsledky: V roce 2005 za\u0159azeni 23 pacienti, 16 mu\u017E\u016F a 7 \u017Een pr\u016Fm\u011Brn\u00FDm v\u011Bkem 72 let, NYHA II-IV, EF LK 36%, pr\u016Fm\u011Brnou koncentrac\u00ED kreatininu 215 mol/l a GFR 0,53 ml/sec. Hospitalizov\u00E1ni do 1 roku byli 4 pacienti a 2 pacienti zem\u0159eli. Pacienti byli l\u00E9\u010Deni: betablok\u00E1tory (96%), inhibitory ACE (70%), sartany (22%), ACEi nebo sartany (78%), spironolaktonem (78%), erytropoetinem (22%). U 19 pacient\u016F s pr\u016Fm\u011Brnou dobou sledov\u00E1n\u00ED 222 55 dn\u00ED do\u0161lo ke zlep\u0161en\u00ED t\u0159\u00EDdy NYHA (p=0,015), zv\u00FD\u0161en\u00ED ejek\u010Dn\u00ED frakce LK (p<0,0001) a poklesu tlaku v plicnici hodnocen\u00E9m neinvazivn\u011B (p<0,00001). Zm\u011Bna GRF nebyla v\u00FDznamn\u00E1 (z 0,53 na 0,48 ml/sec., p = 0,075). Z\u00E1v\u011Bry: multidisciplin\u00E1rn\u00ED p\u0159\u00EDstup v p\u00E9\u010Di o nemocn\u00E9 s kardioren\u00E1ln\u00EDm syndromem je spojen s klinick\u00FDm a hemodynamick\u00FDm zlep\u0161en\u00EDm, nedoch\u00E1z\u00ED ke zhor\u0161en\u00ED ren\u00E1ln\u00EDch funkc\u00ED v kr\u00E1tk\u00E9m \u010Dasov\u00E9m horizontu i p\u0159i pou\u017Eit\u00ED modern\u00ED agresivn\u00ED farmakoterapie srde\u010Dn\u00EDho selh\u00E1n\u00ED." . "Short-Term Effect of Evidence Based Medicine Heart Failure Therapy on Glomerular Fitration Rate in Elderly Patients with"@en . "1"^^ . "Kr\u00E1tkodob\u00FD efekt l\u00E9\u010Dby srde\u010Dn\u00EDho selh\u00E1n\u00ED na v\u00FDvoj glomerul\u00E1rn\u00ED filtrace u star\u0161\u00EDch pacient\u016F s kardioren\u00E1ln\u00EDm syndromem" . . "M\u00E1lek, Filip" . "57" . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . "322669" . . . . . . "0002-8614" . . "12" .